Bioavailability & Solubility

PLATFORM TECHNOLOGY – ​​The 3DNA® Platform for Targeted Drug Delivery

Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.

EXCLUSIVE ONLINE CONTENT

6/6/2018

TxCell Names Lonza as its CAR-Treg Cellular Product Manufacturer

TxCell SA and Lonza Pharma & Biotech recently announced entering into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.